leisure time -WSS

leisure time

author：entertainment 2025-09-28 21:57:34 - browse：8716

Sammy Kimball for STAT

Is Wegovy really a brain drug? Which Alzheimer’s disease treatment works best? And what’s the point of Threads?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

For more on what we cover, here’s the story on GLP-1 drugs and the brain; here’s the latest on Leqembi; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： U.K. sequencing study surfaces new findings about tumor DNA

WSS

Readout Newsletter: Amylyx, Aurinia, and IQVIA

AdventHealth escalates lawsuit against insurance vendor Multiplan

Too many hospitalized Covid

Here’s what’s in the FDA plan to include pregnant women in clinical trials

JPM: CVS says Medicare Advantage patients are impacting profits

Report cites 'urgent' need to recruit more diverse clinical trial participants

focus

leisure time

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Guidelines to prevent youth baseball injuries need more muscle

Goldman Sachs launches $650M fund for life science investments

Medicare proposal to cover medical devices draws a mixed reaction

Feng Zhang CRISPR delivery startup lays off quarter of staff

Moonlake's readout produced a cash windfall. Risks remain

Abbott's new heart device gets FDA advisory panel nod

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: Amylyx, Aurinia, and IQVIA

explore

The FDA must approve intranasal treatments for anaphylaxis

Doctors on social media are being harassed and cyberbullied

The biotech scorecard for Q1: 17 stock

Here’s what’s in the FDA plan to include pregnant women in clinical trials

ACIP vaccine advisory panel sees its vacancies filled

New weight loss drugs work. But how can they best be used?

knowledge

entertainment

entertainment

explore